Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review.
Oncol Ther
; 8(1): 147-160, 2020 Jun.
Article
em En
| MEDLINE
| ID: mdl-32700070
ABSTRACT
Irinotecan-based regimens are used worldwide for the treatment of several recurrent or advanced gastrointestinal malignancies. In this paper we describe the cases of four patients treated in our institution who developed acute dysarthria while receiving intravenous infusion of irinotecan. In all our cases, dysarthria occurred during the infusion of the first course of irinotecan, and then resolved rapidly without any sequelae. Imaging of the brain was performed, but failed to show any evidence of an acute neurological event. We also reviewed the literature on this very uncommon adverse event. The pathogenesis of irinotecan-induced dysarthria is still unknown and is not completely elucidated by the current pharmacodynamic or kinetic explanations; therefore, we could only hypothesize some assumptions.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncol Ther
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália